Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety.
Immunotherapy
; 11(8): 705-723, 2019 06.
Article
em En
| MEDLINE
| ID: mdl-31045464
ABSTRACT
Intratumoral immunotherapy inhibits tumor growth by killing injected tumor cells, thus initiating local and systemic immune responses. Oncolytic viruses are a novel class of intratumoral immunotherapies that show promise for treating solid tumors. Talimogene laherparepvec is a first-in-class, genetically modified, herpes simplex virus type 1-based oncolytic immunotherapy approved for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. This review highlights the dual mechanism of action for talimogene laherparepvec (direct tumor cell lysis and stimulation of local response in tumor microenvironment and systemic immune response in distant metastases), summarizes key preclinical and clinical trials evaluating efficacy and safety of talimogene laherparepvec in melanoma, and describes studies ongoing in other solid tumors.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Produtos Biológicos
/
Herpesvirus Humano 1
/
Terapia Viral Oncolítica
/
Melanoma
Limite:
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article